AR100270A1 - Anticuerpos ang2 - Google Patents

Anticuerpos ang2

Info

Publication number
AR100270A1
AR100270A1 ARP150101338A ARP150101338A AR100270A1 AR 100270 A1 AR100270 A1 AR 100270A1 AR P150101338 A ARP150101338 A AR P150101338A AR P150101338 A ARP150101338 A AR P150101338A AR 100270 A1 AR100270 A1 AR 100270A1
Authority
AR
Argentina
Prior art keywords
ang2
antibodies
cancer
growth factor
vascular endothelial
Prior art date
Application number
ARP150101338A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR100270A1 publication Critical patent/AR100270A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente se refiere a anticuerpos que se unen a angiopoyetina-2 humana (Ang2, por sus siglas en inglés), y pueden ser útiles para tratar cáncer solo y en combinación con inhibidores de la trayectoria de VEGF (factor de crecimiento endotelial vascular), especialmente cáncer accionado por VEGFR2 (receptor 2 del factor de crecimiento endotelial vascular) y Ang2, que incluyen cáncer gástrico, carcinoma hepatocelular, de ovario, colorrectal, y de mama. Célula; proceso para producir un anticuerpo; composición farmacéutica.
ARP150101338A 2014-05-19 2015-05-04 Anticuerpos ang2 AR100270A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462000253P 2014-05-19 2014-05-19

Publications (1)

Publication Number Publication Date
AR100270A1 true AR100270A1 (es) 2016-09-21

Family

ID=54537974

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101338A AR100270A1 (es) 2014-05-19 2015-05-04 Anticuerpos ang2

Country Status (22)

Country Link
US (1) US9695241B2 (es)
EP (1) EP3145544B1 (es)
JP (2) JP6002354B1 (es)
KR (1) KR101943724B1 (es)
CN (1) CN106456755B (es)
AP (1) AP2016009553A0 (es)
AR (1) AR100270A1 (es)
AU (1) AU2015264550B2 (es)
BR (1) BR112016023718A2 (es)
CA (1) CA2945152A1 (es)
CL (1) CL2016002892A1 (es)
EA (1) EA201691889A1 (es)
ES (1) ES2756331T3 (es)
IL (1) IL248145A0 (es)
MX (1) MX2016015151A (es)
NZ (1) NZ724877A (es)
PE (1) PE20161404A1 (es)
PH (1) PH12016502297A1 (es)
SG (1) SG11201608418PA (es)
TN (1) TN2016000442A1 (es)
TW (1) TWI551610B (es)
WO (1) WO2015179166A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7177284B2 (ja) * 2019-02-25 2022-11-22 ファームアブシン・インコーポレイテッド 抗ａｎｇ２抗体及びその用途
TW202115112A (zh) * 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
KR20220054689A (ko) 2019-10-15 2022-05-03 일라이 릴리 앤드 캄파니 재조합적으로 조작된, 리파제/에스테라제-결핍 포유동물 세포주

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
MX2007004247A (es) * 2004-10-19 2007-06-12 Amgen Inc Agentes de aglutinacion especifica a angiopoyetina-2.
ES2371083T3 (es) * 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
BRPI0809026A2 (pt) * 2007-03-20 2014-09-23 Lilly Co Eli Anticorpos antiesclerotina
AU2009209251B8 (en) 2008-01-28 2015-03-26 Medimmune Limited Stabilized Angiopoietin-2 antibodies and uses thereof
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
AR100271A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Compuestos de vegfr2 / ang2

Also Published As

Publication number Publication date
JP6231632B2 (ja) 2017-11-15
US9695241B2 (en) 2017-07-04
EP3145544B1 (en) 2019-10-09
KR101943724B1 (ko) 2019-01-29
TW201605893A (zh) 2016-02-16
BR112016023718A2 (pt) 2017-10-17
CN106456755B (zh) 2020-01-07
PH12016502297A1 (en) 2017-02-13
SG11201608418PA (en) 2016-11-29
EA201691889A1 (ru) 2017-04-28
TN2016000442A1 (en) 2018-04-04
CA2945152A1 (en) 2015-11-26
CN106456755A (zh) 2017-02-22
JP2017031166A (ja) 2017-02-09
CL2016002892A1 (es) 2017-06-23
NZ724877A (en) 2018-02-23
KR20160145158A (ko) 2016-12-19
IL248145A0 (en) 2016-11-30
EP3145544A4 (en) 2017-12-27
EP3145544A1 (en) 2017-03-29
TWI551610B (zh) 2016-10-01
AU2015264550B2 (en) 2017-11-02
JP6002354B1 (ja) 2016-10-05
WO2015179166A1 (en) 2015-11-26
PE20161404A1 (es) 2016-12-28
MX2016015151A (es) 2017-03-07
US20150329627A1 (en) 2015-11-19
ES2756331T3 (es) 2020-04-27
AU2015264550A1 (en) 2016-10-27
JP2016532633A (ja) 2016-10-20
AP2016009553A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
PE20171383A1 (es) Receptores de antigeno quimericos anti-dll3 y metodos de uso
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
CU20150128A7 (es) Conjugados fármaco-anticuerpo
UY35399A (es) Conjugados de fármacos con anticuerpos
NI201700001A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
PE20170264A1 (es) Anticuerpos monoclonales contra el epitope de her2 y sus metodos de uso
PE20170704A1 (es) Agente terapeutico que induce citotoxicidad
SG10201810108PA (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
BR112017009764A2 (pt) anticorpos biespecíficos e métodos de uso em oftalmologia
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
AR103477A1 (es) Compuestos de vegfa / ang2
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
AR100270A1 (es) Anticuerpos ang2
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
AR100271A1 (es) Compuestos de vegfr2 / ang2
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.

Legal Events

Date Code Title Description
FB Suspension of granting procedure